Holen Sie sich die Stockscreener-App
178.24
0.42%
0.75
Handel nachbörslich:
178.24
Schlusskurs vom Vortag:
$177.49
Offen:
$177.7
24-Stunden-Volumen:
1.16M
Relative Volume:
0.95
Marktkapitalisierung:
$17.92B
Einnahmen:
$3.10B
Nettoeinkommen (Verlust:
$668.60M
KGV:
27.40
EPS:
6.5044
Netto-Cashflow:
$831.30M
1W Leistung:
+6.24%
1M Leistung:
+9.27%
6M Leistung:
+31.47%
1J Leistung:
+38.45%
1-Tages-Spanne:
$175.28
$178.62
1-Wochen-Bereich:
$168.26
$178.75
52-Wochen-Spanne:
$122.14
$178.75
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
178.24 | 17.85B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
16.75 | 53.59B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.75 | 43.33B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.24 | 40.35B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.10 | 31.98B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
554.34 | 23.93B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences (NBIX) Starts Phase 2 CAH Study In Children Under 4 - Yahoo Finance
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight - Yahoo Finance
Neurocrine Biosciences outlines its neurology focus as a mid-cap biotech name - AD HOC NEWS
Insider option exercise and 10b5-1 sales at NBIX (NBIX) - Stock Titan
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - AOL.com
Neurocrine Biosciences stock hits all-time high at 176.1 USD - Investing.com
Neurocrine Biosciences stock hits all-time high at 176.1 USD By Investing.com - Investing.com UK
Neurocrine Biosciences stock and its role in neurological treatments - AD HOC NEWS
RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating - Moomoo
Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside - DirectorsTalk Interviews
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen - ChartMill
NBIXNeurocrine Biosciences Inc Options - Finviz
What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders - Sahm
Neurocrine Biosciences Inc (NBIX) Stock Up 3.9% and Still Underv - GuruFocus
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX) - Seeking Alpha
Zacks.com featured highlights include Neurocrine Biosciences, MYR Group, Block, Delek US Holdings and Dycom Industries - Yahoo Finance
Neurocrine (NBIX) Reports Clinically Meaningful Benefits in 94% of Patients Treated for Tardive Dyskinesia - Yahoo Finance
Neurocrine starts phase 2 trial of crinecerfont in infants with CAH - Investing.com
Neurocrine tests CRENESSITY in infants and toddlers with rare CAH - Stock Titan
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know - Yahoo Finance
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup - ChartMill
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia - Sahm
Price to book forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Neurocrine (NBIX) legal chief exercises options and sells 10,000 shares - Stock Titan
Neurocrine Biosciences' Ingrezza Momentum Seen Supporting 2026 Guidance Upgrade, UBS Says - Moomoo
Price to book forward of Neurocrine Biosciences, Inc. – MIL:1NBIX - TradingView
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $208 - Moomoo
9,800-share Form 144 filed for NBIX (NASDAQ: NBIX) - Stock Titan
Bull of the Day: Neurocrine Biosciences (NBIX) - TradingView
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day - The Globe and Mail
Neurocrine Biosciences stock hits all-time high at 169.62 USD By Investing.com - Investing.com Nigeria
Neurocrine Biosciences stock hits all-time high at 169.62 USD - Investing.com
Neurocrine Biosciences, Inc.(NasdaqGS: NBIX) dropped from Russell 1000 Dynamic Index - marketscreener.com
Neurocrine Biosciences (NBIX) Is Up 6.5% After CRENESSITY Shows Broad CAH Benefits at ENDO 2026 – Has The Bull Case Changed? - Yahoo Finance
Neurocrine Biosciences (NBIX) Unveils New CRENESSITY Data For Classic CAH And Rare Subtype - Yahoo Finance
Neurocrine Biosciences (NBIX) Showed New CRENESSITY Data, Is The Stock Still Cheap? - simplywall.st
Neurocrine Biosciences (NBIX): High Growth NASDAQ Stocks to Buy Now - Insider Monkey
Neurocrine Biosciences (NBIX): High Growth Stocks to Buy Right Now - Insider Monkey
Neurocrine Biosciences, Inc. Actuals & Estimates (NASDAQ:NBIX) - TradingView
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June - Investing.com UK
Form 144 NEUROCRINE BIOSCIENCES INC For: 26 June By Investing.com - Investing.com Australia
Price to earnings forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView
Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Enterprise value to EBITDA forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Price to sales forward of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
Costco Stock And 2 Low Risk Picks Built For Volatile Markets - simplywall.st
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):